References
- Sandler SG, Roseff SD, Domen RE, Shaz B, Gottschall JL. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists. Arch Pathol Lab Med 2014;138:620–5.
- Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion 2015;55:680–9.
- Flegel WA, Denomme GA, Queenan JT, et al. It’s time to phase out “serologic weak D phenotype” and resolve D types with RHD genotyping including weak D type 4. Transfusion 2020;60:855–9.
- Wagner FF, Gassner C, Müller TH, Schönitzer D, Schunter F, Flegel WA. Molecular basis of weak D phenotypes. Blood 1999;93:385–93.
- Pirelli KJ, Pietz BC, Johnson ST, Pinder HL, Bellissimo DB. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D. Prenat Diagn 2010;30:1207–12.
- Grootkerk-Tax MG, Maaskant-van Wijk PA, van Drunen J, van der Schoot CE. The highly variable RH locus in nonwhite persons hampers RHD zygosity determination but yields more insight into RH-related evolutionary events. Transfusion 2005;45:327–37.
- Wagner FF, Flegel WA. RHD gene deletion occurred in the Rhesus box. Blood 2000;95:3662–8.
- Wagner FF, Moulds JM, Flegel WA. Genetic mechanisms of Rhesus box variation. Transfusion 2005;45:338–44.
- Wagner FF, Moulds JM, Tounkara A, Kouriba B, Flegel WA. RHD allele distribution in Africans of Mali. BMC Genet 2003;4:14.
- Seltsam A, Wagner FF, Salama A, Flegel WA. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion 2003;43:1563–6.
- Beadling W, Cooling L. Immunohematology. In: McPherson R, Pincus M, Eds. Henry’s Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, PA: Elsevier, 2007: 617–36.
- Westhoff CM, Nance S, Lomas-Francis C, Keller M, Chou ST. Experience with RHD*weak D type 4.0 in the USA. Blood Transfus 2019;17:91–3.
- Ouchari M, Srivastava K, Romdhane H, Jemni Yacoub S, Flegel WA. Transfusion strategy for weak D type 4.0 based on RHD alleles and RH haplotypes in Tunisia. Transfusion 2018;58:306–12.
- Flegel WA, Peyrard T, Chiaroni J, Tournamille C, Jamet D, Pirenne F. A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes. Blood Transfus 2019;17:89–90.
- Evans ML, Holmes B, Dowling K, et al. Evaluating automated titre score as an alternative to continuous flow analysis for the prediction of passive anti-D in pregnancy. Transfus Med 2021;31:36–42.
- Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015;55:2095–103.
- Laget L, Izard C, Durieux-Roussel E, et al. Relevance and costs of RHD genotyping in women with a weak D phenotype. Transfus Clin Biol 2019;26:27–31.
- Flegel WA. How I manage donors and patients with a weak D phenotype. Curr Opin Hematol 2006;13:476–83.